<DOC>
	<DOCNO>NCT03077659</DOCNO>
	<brief_summary>Open-label , dose rising , Phase IIa trial intratumorally-injected NanoPac 6 , 10 , 15 mg/mL subject prostate cancer schedule prostatectomy .</brief_summary>
	<brief_title>Trial NanoPac Focal Therapy Subjects With Prostate Cancer</brief_title>
	<detailed_description>In open-label , dose rising , Phase IIa trial expand cohort dose NanoPac determine best tolerability safety profile , subject prostate cancer schedule prostatectomy NanoPac inject image guidance directly lobe prostate dominant lesion 4 week prior prostatectomy . The study include dose escalation phase dose confirmation phase . In dose escalation phase , NanoPac concentrations 6 , 10 , 15 mg/mL injection volume 20 % lobe prostate contain dominant lesion study cohort 3 , cohort enrol sequentially start low concentration . Following DSMB review cohort data next cohort may begin enrol , additional 3 current dose may enrol , first dose provide adequate safety tolerability study may halt . The dose determine suitable evaluation , define high dose acceptable safety tolerability profile determine DSMB , enroll additional subject provide cohort 12 subject dose level . Tumor volume serum prostate-specific antigen ( PSA ) determine prior NanoPac injection . Pharmacokinetic sample , PSA , ejaculate collect interval injection prostatectomy . Imaging mpMRI perform prior NanoPac injection prior prostatectomy . Prostate pelvic lymph node excise prostatectomy evaluate .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<criteria>Male ; 18 year age old Histopathologically proven adenocarcinoma , Gleason grade ≥ 7 prostate plan radical prostatectomy ; appropriate treatment paclitaxel therapy ECOG 0 1 ( Appendix A ) Willing use appropriate contraception time NanoPac injection prostatectomy Prostate size ≥ 50 cc Prior prostatectomy Anticipated use concomitant chemotherapy ( protocol specify agent ) , immunotherapy , radiation therapy , prior surgery Treatment prior investigational agent within 30 day first dose investigational medication Any previous local treatment prostate ( i.e . radiation ) Any condition ( e.g . psychiatric disorder ) , opinion Investigator , may interfere patient 's ability comply study requirement visit schedule Known sensitivity study medication component History prior malignancy remission &gt; 5 year , exception basal cell squamous cell carcinoma .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>